# Alison M Mcdonnell

List of Publications by Year
in descending order



| 22 | 590 | 687363 13 | 677142 22 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 22 | 22 | 22 | 1317 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Annals of Oncology, 2015, 26, 2483-2490. | 1.2 | 76 |
| 2 | Tumorâ€infiltrating dendritic cells exhibit defective crossâ€presentation of tumor antigens, but is reversed by chemotherapy. European Journal of Immunology, 2015, 45, 49-59. | 2.9 | 64 |
| 3 | Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins?. Clinical and Developmental Immunology, 2010, 2010, 1-9. | 3.3 | 59 |
| 4 | Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation. Journal of Immunology, 2009, 183, 7898-7908. | 0.8 | 58 |
| 5 | Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. OncoImmunology, 2016, 5, e1066062. | 4.6 | 55 |
| 6 | Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. Frontiers in Immunology, 2020, 11, 584423. | 4.8 | 39 |
| 7 | CD8Î±<sup>+</sup> DC are not the sole subset crossâ€presenting cellâ€associated tumor antigens from a solid tumor. European Journal of Immunology, 2010, 40, 1617-1627. | 2.9 | 33 |
| 8 | Contribution of the immune system to the chemotherapeutic response. Seminars in Immunopathology, 2011, 33, 353-367. | 6.1 | 30 |
| 9 | Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy. Cells, 2020, 9, 565. | 4.1 | 28 |
| 10 | PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Lung Cancer, 2016, 93, 9-16. | 2.0 | 27 |
| 11 | Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation. OncoImmunology, 2012, 1, 840-846. | 4.6 | 21 |
| 12 | Immune checkpoint inhibition for the treatment of mesothelioma. Expert Opinion on Biological Therapy, 2019, 19, 697-706. | 3.1 | 18 |
| 13 | Restoration of defective cross-presentation in tumors by gemcitabine. OncoImmunology, 2015, 4, e1005501. | 4.6 | 16 |
| 14 | Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. Scientific Reports, 2021, 11, 15312. | 3.3 | 15 |
| 15 | Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression. Cells, 2021, 10, 56. | 4.1 | 14 |
| 16 | Malignant Pleural Effusionsâ€”A Window Into Local Anti-Tumor T Cell Immunity?. Frontiers in Oncology, 2021, 11, 672747. | 2.8 | 9 |
| 17 | Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. BMC Cancer, 2017, 17, 417. | 2.6 | 8 |
| 18 | Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Research Notes, 2018, 11, 864. | 1.4 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Diverse Anti-Tumor Immune Potential Driven by Individual IFNÎ± Subtypes. Frontiers in Immunology, 2020, 11, 542. | 4.8 | 6 |
| 20 | Non-severe burn injury increases cancer incidence in mice and has long-term impacts on the activation and function of T cells. Burns and Trauma, 2022, 10, tkac016. | 4.9 | 3 |
| 21 | Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations. Frontiers in Immunology, 2022, 13, . | 4.8 | 3 |
| 22 | A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert Review of Anticancer Therapy, 2021, 21, 465-474. | 2.4 | 1 |